Cell lines with latent immunodeficiency virus and methods of use thereof
View Patent ↗The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency virus-based retroviral vector. Under basal in vitro culture conditions, the immunodeficiency virus is latent, and the expression of the latent immunodeficiency virus can be reactivated. The invention further provides methods of making a subject cell. The invention further provides screening methods for identifying agents that activate a latent immunodeficiency virus; and screening method for identifying agents that block reactivation of latent immunodeficiency virus expression in response to T cell activation signals. The invention further provides agents identified in the subject screening assays. The invention further provides methods of treating an immunodeficiency virus infection.
1. An isolated T cell line that comprises a recombinant transcription-competent immunodeficiency virus or vector integrated into the genome of the cell, wherein the virus or vector comprises a functional transactivation response element (TAR) and comprises a nucleotide sequence encoding a functional transactivator protein (Tat), wherein the immunodeficiency virus is latent under basal in vitro culture conditions, and wherein expression of the latent immunodeficiency virus can be reactivated.
2. The cell line of claim 1 , wherein said cell is an immortalized cell line.
3. The cell line of claim 1 , wherein said immunodeficiency virus is human immunodeficiency virus (HIV).
4. The cell line of claim 3 , wherein said immunodeficiency virus is HIV-1.
5. An isolated immortalized cell that comprises a recombinant transcription-competent immunodeficiency virus or vector, wherein the virus or vector comprises a nucleotide sequence encoding a selectable marker operably linked to an immunodeficiency virus promoter, wherein said virus or vector is integrated into the genome of the cell, wherein the virus or vector comprises a functional transactivation response element (TAR) and comprises a nucleotide seciuence encoding a functional transactivator nrotein (Tat), wherein the virus or vector is latent and transcriptionally silent under basal in vitro culture conditions, and wherein expression of the latent virus or vector can be reactivated.
6. The cell line of claim 1 , wherein the latent virus or vector is reactivated by an activator of NF-κB or a histone deacetylase inhibitor.
7. The cell of claim 5 , wherein the marker is a fluorescent protein.
8. The cell line of claim 6 , wherein the activator of NK-κB is selected from tetradecanoyl phorbol acetate, tumor necrosis factor-α, phytohemagglutinin, and an anti-CD3 antibody.
9. The cell line of claim 6 , wherein said histone deacetylase inhibitor is trichostatin A.
10. The cell of claim 5 , wherein the latent virus or vector is reactivated by an activator of NF-κB or a histone deacetylase inhibitor.
11. The cell of claim 10 , wherein the activator of NK-κB is selected from tetradecanoyl phorbol acetate, tumor necrosis factor-α, phytohemagglutinin, and an anti-CD3 antibody.
12. The cell of claim 10 , wherein said histone deacetylase inhibitor is trichostatin A.
13. The cell of claim 5 , wherein said immunodeflciency virus is a human immunodeficiency virus (HIV).